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Abstract: Sultopride or sulpiride was administered to 26 schizophrenic patients. In 
the male patients， there was a significant correlation between serum concentrations of 
sultopride and sulpiride and prolactin response. In the female patients， there was no 
significant correlation between them. In sultopride treatment， prolaction response was 
suggested to be predictive of a good therapeutic response. 
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INTRODUCTION 
The ability of neuroleptics to influence the endocrine system is well documented. Matsuoka 
et al1) reported that 65 % of schizophrenic female patients with amenorrhea， 78 % of schizo-
phrenic patients with galactorrhea and 58 % of schizophrenic male patients developed hyper同
prolactinemia， in which al of those patients were under the chronic neuroleptic treatment. 
The prolactin hormone CPRL) is under doparminergic inhibitory control so that neuroleptics 
increase its secretion2). The role of PRL concentration as an indicator of doparminergic 
activity has yielded controversial results. It has been reported that a single dose of haloperidol 
produces a weaker PRL secretion response in schizophrenic patients than in normal controls3)， 
and Kulkarni et a14) reported a significant inverse relationship between the PRL response and 
severity of delusional symptoms 
Sultopride and sulpiride are antipsychotic drugs belonging to the class of substituted ben-
zamides. Sulpiride is reported to be very potent in stimulating PRL release in rats5) and 
humans6)， while sultopride， like sulpiride， also stimulates PRL secretion in rats7) and humans8). 
In the present study， we wanted to investigate the clinical profile or difference of these drugs 
and also to determine whether changes in PRL response to neuroleptics， in serum PRL levels 
also reflect central doparminergic activity. 
SUBJECTS AND METHODS 
The study comprised 26 patients with a mean age of 41.5土12.4year (16 males with a mean 
age of 4l. 8土15.4，and 10 females with a mean age of 42.5士11.7，of whom 10 had an irregular 
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menstrual cycle and 2 had a regular menstrual cycle)， who were diagnosed with schizophrenia 
based on DSM-I1IR criteria and had been receiving treatment at Nara Medical University 
Hospital. There was no significant difference as to mean age and period of illness between the 



























E .  ー」
江
宅25
も。 0.5 1.0 1.5 2.0 2.5 3.0 
。ムニ
0.0 
. .‘ . r，

































Fig. 2. Significant correlation betweenムPRL(Y ng/ml) and conc巴ntration(Xμg/ml) 
of drugs in the male patients. 
T. Kishimoto， etal. 
male group and the female group. All patients gave informed consent to this study. 
Subjects were divided into two groups， A and B， and were administered sultopride or sulpiride 
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Fig. 3. Tim巴 courseofムPRLrespons巴toadmisistration of sultoprid巴 andsulpirid巴.
ムPRLis defin巴das the incr巴mentof PRL compared to base level (0 w巴ek).
Sulpiride 
ed orally for the first 4 weeks and then sulpiride 400 mg/ day was administered orally for 4 
weeks. B: Sulpiride 400 mg/ day was administered orally for the first 4 weeks and then 
sultopride 400 mg/ day was administered orally for 4 weeks. Medication regimens prior to this 
study were continued without any change. 
Once the subjects were enrolled in the study， their symptoms were rated on the 18-item Brief 
Psychiatric Rating Scale CBPRS)9) by their primary physician at 0， 4， and 8 weeks of the study. 
This was based on earlier five-dimensional model BPRS subtypes10)， which include the dimen-
sions of 1) Anxiety-Depression Csomatic concern， anxiety， guilt feelings， and depressive 
mood) ; 2) Anergia Cemotional withdrawal， motor retardation， blunted affect， and disorienta-
tion) ; 3) Thought Disturbance Cconceptual disorganization， grandiosity， hallucinatory behav凹
ior， and unusual thought content) ; 4) Activation Ctension， mannerisms and posturing， and 
excitement) ; 5) Hostile-Suspiciousness Chostility， suspiciousness， and uncooperativeness). 
In order to determine whether changes in PRL during treatment were predictive of therapeu-
tic response to neuroleptics， we investigated the correlation betweenムPRLat 1 week and the 
degree of improvement of BPRS total score at 4 weeks or between them at 5 weeks and 8 
weeks. 
Blood samples were taken routinely at 8 : 30 a. m. ; just before the daily medication in 0， 1， 
2， 4， 5， 6， and 8 weeks after the beginning of the study for estimating serum PRL levels， 
sultopride levels and sulpiride levels. PRL was measured by radioimmunoassay using Spac-S 
prolactin Kit， Daiichi Radioisotope Laboratories.， Tokyo. Serum concentrations of sultopride 
and sulpiride were measured by performing high-performance liquid chromatography with 
electrochemical detection CHPLC-ECD) by Teijin Bio Laboratories， Inc. Tokyo. 


























合p<0.05 (Mann-Whitney U test) 











































Fig. 5. BPRS cluster analysis of clinical efect of sultopride and sulpiride 
Stastistical analysis of the data was performed with the paired t-test and Mann-Whitney U 
-test. Values of p < 0.05 were considered to be significant. 
RESULTS 
Sultopride in A group and sulpiride in B group were not detectable at 5 weeks in al patients. 
In the males， there was a significant correlation between serum concentrations of sultopride or 
sulpiride andムPRLin both A and B groups (Fig. 2).ムPRLwas defined as the increment of 
PRL compared to base level (0 week). The severity of drug-induced hyperprolactinemia was 
significantly correlated with drug concentration in peripheral blood in the males. On the other 
hand， inthe females， there was no significant correlation between them. Time courses of drug 
levels andムPRLsare presented in Fig. 3. From Fig. 3， the area under the curve (AUC) is 
calculated and i1lustrated in Fig. 4. AUC of sulpiride in the females was significantly greater 
than in the males in both A group and B group， although AUC of sultopride did not significantly 
differ between genders. In each gender group， there was neither any significant difference 
between AUC of sultopride in A group and AUC of sultopride in B group， nor any significant 
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difference between AUC of sulpiride in A group and AUC of sulpiride in B group. 
To investigate the clinical profiles of these benzamide drugs， we compared these antipsy-
chotic effects by evaluating BPRS (Fig. 5). BPRS total scores were significantly decreased by 
sultopride administration and by sulpiride administration. For each BPRS cluster， "Anxiety-
Depression" and "Activation" were significantly ameliorated by both administration of sulto-
pride and sulpride， "Thought Disturbance" and "Hostile-Suspiciousness" were significantly 
ameliorated only by administration of sultopride. 
There was a significant correlation between sPRL at 1 week and the degree of improvement 
of BPRS total score at 4 weeks in A group (sultopride). There was no significant correlation 
between them at 5 weeks and 8 weeks in A group (sulpiride)， and there was no significant 
relationship between them in B group (sulpiride and sultopride). It was suggested that the 
greaterムPRLat 1 week of treatment might be a predictor of a better response to 4 weeks 
sultopride treatment. 
DISCUSSION 
Sultopride and sulpiride were potent to induce hyperprolactinemia in both male and female 
patients. In the male patients， there was a significant correlation between the serum concentra-
tion of both drugs andムPRL，which suggested a peripheral blood effect on doparminergic 
activity of the anterior lobe of the pituitary. In the female patients，ムPRLwas greater than 
in the male patients and there was no relationship between serum concentration and sPRL， 
which is consistent with the report of Miyachi et a18) and inconsistent with the report of 
Bjerkenstedt et ap1). The mechanism of PRL secretion response in females be complicated， 
since fluctuating PRL levels throughout the menstrual cycle are well documented12). 
Both sultopride and sulpiride decreased BPRS total score， Anxiety-Depression score and 
Activation score. Sulpiride also decreased Thought Disturbance score and Hostile-Suspiciou-
ness score， while sulpiride did not decrease these scores. It was suggested that sultopride had 
a more potent and wider spectrum than sulpiride. 
There was a significant correlation between sPRL and the results of treatment with sulto-
pride in A group. This might suggest great sPRL might be predictive of a good therepeutic 
response to neuroleptic treatment. However， there was no significant correlation between them 
with sulpiride treatment in A group and B group， with sultopride treatment in B group. In 
might be that benzamide derivatives have some effect on serotonergic activity， since the 
general consensus in the literature in that serotonin directly stimulates the release of PRL-
releasing factor (PRF)山 14)Some caution must be applied in interpretingムPRLas an indicator 
of doparminergic activity. 
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